JNJ

Johnson & Johnson

A diversified med-tech and pharma compounder — slower, litigated, still wide.

WideDecadeFairClassic

Longhold

Earnings

Moat

Hold

Ten-year thesis

After the consumer spin, J&J is innovative medicine plus MedTech. Pipelines, hospital relationships, and a fortress balance sheet define it. A ten-year hold is a bet on the device franchise and a few durable drugs, with litigation as a known haircut. Earnings are high quality; growth is not exciting. A ballast name, like PG, with more patent-cliff work.

The moat

Hospital switching costs in devices, patents, scale in sales forces, and brand with clinicians. Pharma patents expire; devices linger.

Switching costs74

Pain, risk, or retraining required to leave.

Network effects30

The product gets better as more people use it.

Intangibles & IP84

Patents, data, licenses, process knowledge, regulation.

Scale advantage88

Fixed costs spread over a volume rivals cannot match.

Cost advantage70

Structural ability to be the low-cost producer.

Brand86

Pricing power from trust, habit, or identity.

Tech overlay

MedTech has a real engineering cycle (robotics, electrophysiology). It is still closer to a Buffett healthcare compounder than to a software name. Fine to own beside tech, not instead of thinking.

What can break it

Patent cliffs
Litigation tails
Hospital capex cycles

Earnings path

USD billions, illustrative 2016–2025 series

Owner metrics

P/E

17.0×

P/FCF

16.0×

ROIC

14%

ROE

22%

FCF conversion

90%

Debt / equity

0.50

Gross margin

69%

Op. margin

26%

10y rev CAGR

10y EPS CAGR

Owner earnings

$22.0B

Mkt cap

$380B

Owner earnings yield 5.8%. Yield is judged against quality, not against a single hurdle — a fortress can be fairly priced at a lower yield than a fragile name.

MedTechPharmaDefensive